Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2019 | Managing CRS after anti-BCMA CAR-T for myeloma

He Huang • 17 May 2019
COMy 2019
Multiple Myeloma CAR-T Tocilizumab

He Huang, MD, PhD, of Zhejiang University School of Medicine, Zhejiang, China discusses how the majority of patients receiving BCMA CAR-T therapies suffer from cytokine release syndrome (CRS). Dr Huang also discusses different treatments including the anti-interleukin-6 antibodies. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from He Huang

An update on the experience with CAR T-cell therapy in China 3:09
An update on the experience with CAR T-cell therapy in China
He Huang • 16 Feb 2024
Novel CAR T-cell therapies for hematological malignancies: exploring new targets 4:17
Novel CAR T-cell therapies for hematological malignancies: exploring new targets
He Huang • 16 Feb 2024
HSCT & CAR-T therapy during COVID-19: Chinese experience 6:29
HSCT & CAR-T therapy during COVID-19: Chinese experience
He Huang • 2 Feb 2021
CAR-T cells for myeloma: experience from China 2:37
CAR-T cells for myeloma: experience from China
He Huang • 16 May 2019

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals